Developer docs
API playgroundTry for free, no card

Search company profiles

Receptor

Full company profile

uuid000vfez

Namestring
Receptor
Legal namestring
Receptor Partners, LLC
Websiteurl
receptor.vc
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Receptor (legal name Receptor Partners, LLC) is a New York-based venture capital firm founded in 2021 that invests exclusively in the psychedelic medicine sector. The firm deploys equity capital and provides strategic support to early-stage companies developing novel therapeutic approaches for mental health conditions. Its stated positioning is investing in "the future of psychedelic medicine," addressing a funding gap in psychedelic medicine research and development and supporting innovation in mental health treatment through strategic capital deployment.

Receptor is a private investment entity rather than a product or software company; it does not sell products or services and has no disclosed pricing, revenue model, or commercial distribution. Its disclosed portfolio comprises eight companies developing psychedelic-based therapeutics and related technologies: Beckley Psytech, Psilera, Mind State Design, Brightminds (Brightminds Bio), Tactogen, Delix (Delix Therapeutics, focused on non-hallucinogenic psychedelic analogs), Freedom Bio, and Cybin. The firm characterizes these as portfolio company investments in its "core" strategic tier.

The company is a small operation (1–10 employees) headquartered in New York, United States, structured as an LLC with no disclosed parent, subsidiaries, institutional backers, or public listing. Investor relations are handled through a single disclosed contact ([email protected]). As a venture firm, it likely relies on private networking, industry conferences, and direct outreach for deal sourcing and investor relations, though marketing activities are not publicly disclosed.

Short descriptiontext

Receptor is a New York-based venture capital firm founded in 2021 that invests exclusively in early-stage psychedelic medicine companies developing novel therapeutics for mental health conditions, backing a portfolio that includes Beckley Psytech, Delix, Cybin, and Psilera.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital investing, psychedelic medicine, early-stage biotech, mental health therapeutics, life sciences funding
Industry1 code
1Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryYes
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital (Psychedelic Medicine)
Social media profiles1 record
Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Receptor is a venture capital firm that provides equity investment capital to early-stage companies developing psychedelic-based therapeutics and supporting technologies for mental health conditions. The firm deploys and manages a thematic portfolio across psychedelic drug developers and research platforms rather than selling any standalone product or service. Investment activity is concentrated on portfolio companies such as Beckley Psytech, Psilera, Mind State Design, Brightminds, Tactogen, Delix, Freedom Bio, and Cybin.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Receptor is a venture capital firm that provides investment capital and strategic support to early-stage companies in the psychedelic medicine sector. The firm does not offer a product platform or software services; instead, it deploys equity investment across a portfolio of companies developing psychedelic-based therapeutics and related technologies. Receptor's portfolio includes Beckley Psytech, Psilera, Mind State Design, Brightminds, Tactogen, Delix, Freedom Bio, and Cybin, representing the firm's investment focus rather than a product ecosystem.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Receptor

Venture Capital (Psychedelic Medicine)receptor.vc

Receptor is a New York-based venture capital firm founded in 2021 that invests exclusively in early-stage psychedelic medicine companies developing novel therapeutics for mental health conditions, backing a portfolio that includes Beckley Psytech, Delix, Cybin, and Psilera.

What Receptor does

Receptor (legal name Receptor Partners, LLC) is a New York-based venture capital firm founded in 2021 that invests exclusively in the psychedelic medicine sector. The firm deploys equity capital and provides strategic support to early-stage companies developing novel therapeutic approaches for mental health conditions. Its stated positioning is investing in "the future of psychedelic medicine," addressing a funding gap in psychedelic medicine research and development and supporting innovation in mental health treatment through strategic capital deployment.

Receptor is a private investment entity rather than a product or software company; it does not sell products or services and has no disclosed pricing, revenue model, or commercial distribution. Its disclosed portfolio comprises eight companies developing psychedelic-based therapeutics and related technologies: Beckley Psytech, Psilera, Mind State Design, Brightminds (Brightminds Bio), Tactogen, Delix (Delix Therapeutics, focused on non-hallucinogenic psychedelic analogs), Freedom Bio, and Cybin. The firm characterizes these as portfolio company investments in its "core" strategic tier.

The company is a small operation (1–10 employees) headquartered in New York, United States, structured as an LLC with no disclosed parent, subsidiaries, institutional backers, or public listing. Investor relations are handled through a single disclosed contact ([email protected]). As a venture firm, it likely relies on private networking, industry conferences, and direct outreach for deal sourcing and investor relations, though marketing activities are not publicly disclosed.

Receptor firmographics

Firmographics
Name
Receptor
Legal name
Receptor Partners, LLC
Website
https://receptor.vc
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Receptor is a New York-based venture capital firm founded in 2021 that invests exclusively in early-stage psychedelic medicine companies developing novel therapeutics for mental health conditions, backing a portfolio that includes Beckley Psytech, Delix, Cybin, and Psilera.
Ownership category
akta.pro rank

Receptor industry classification

Industry
Product category
Venture Capital (Psychedelic Medicine)
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro primary industry
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

  • Venture capital investing
  • Psychedelic medicine
  • Early-stage biotech
  • Mental health therapeutics
  • Life sciences funding

Where Receptor is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Receptor business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Receptor product offering

Product offering

Core offering

Receptor is a venture capital firm that provides equity investment capital to early-stage companies developing psychedelic-based therapeutics and supporting technologies for mental health conditions. The firm deploys and manages a thematic portfolio across psychedelic drug developers and research platforms rather than selling any standalone product or service. Investment activity is concentrated on portfolio companies such as Beckley Psytech, Psilera, Mind State Design, Brightminds, Tactogen, Delix, Freedom Bio, and Cybin.

Product overview

Receptor is a venture capital firm that provides investment capital and strategic support to early-stage companies in the psychedelic medicine sector. The firm does not offer a product platform or software services; instead, it deploys equity investment across a portfolio of companies developing psychedelic-based therapeutics and related technologies. Receptor's portfolio includes Beckley Psytech, Psilera, Mind State Design, Brightminds, Tactogen, Delix, Freedom Bio, and Cybin, representing the firm's investment focus rather than a product ecosystem.

Differentiator

Problem solved

Functional benefit

Companies that use Receptor

Customer profile

Ideal customer profiles1 record

Receptor technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Receptor partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights2 records

Receptor competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Receptor social profiles

Digital presence

Receptor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Receptor leadership team

Management profile

Number of profiles

Receptor funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Receptor M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Receptor

What does Receptor do?

Receptor is a venture capital firm that provides equity investment capital to early-stage companies developing psychedelic-based therapeutics and supporting technologies for mental health conditions. The firm deploys and manages a thematic portfolio across psychedelic drug developers and research platforms rather than selling any standalone product or service. Investment activity is concentrated on portfolio companies such as Beckley Psytech, Psilera, Mind State Design, Brightminds, Tactogen, Delix, Freedom Bio, and Cybin.

Is Receptor a public or private company?

Receptor is a private company. It is classified as unknown and is currently operating.

When was Receptor founded?

Receptor was founded in 2021. It employs 1 to 10 people.

Where is Receptor based?

Receptor is headquartered in New York, United States, in the North America region.

Does Receptor have an API?

No public API is recorded for Receptor.

What industry is Receptor in?

Receptor's product category is Venture Capital (Psychedelic Medicine). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales